Adderall Antitrust Suit Should Stay Buried, 2nd Circ. Hears

Law360, New York (October 04, 2013, 5:46 PM ET) -- Shire LLC pushed back Friday against two drug wholesalers' bid to revive a consolidated class action alleging Shire stifled generic-drug competition for its blockbuster attention deficit hyperactivity disorder treatment Adderall XR, saying the lower court correctly ruled that Shire's patent licensing agreements didn't raise an antitrust issue.

Shire's brief to the Second Circuit backed a March ruling by U.S. District Judge Victor Marrero dismissing the suit by Louisiana Wholesale Drug Co. Inc. and Value Drug Co. Inc. that claimed Shire artificially inflated prices by holding back...
To view the full article, take a free trial now.
Try Law360 for free for seven days
Already a subscriber? Click here to login

Already have access?

  1. Forgot your password?
  2. Sign In

Get instant access to the one-stop news source for business lawyers